Therefore, experimental group dosing in the in vivo Nalm-6 ALL tumor model study is denoted as low dose (2.8 × 106 T cell yielding an effective 1 × 106 BAFF-R CAR T cells) or high dose (5.6 × 106 T cell yielding an effective 2 × 106 BAFF-R CAR T cells) (Fig. 2d). The gene discussed is TNFRSF13C; the disease is neoplasm.